Use, Safety, and Efficacy of Single-Patient Use of the US Food and Drug Administration Expanded Access Program.
Where this comes from
- Record sourced from PubMed, PMID 30816938.
- Also identified by DOI 10.1001/jamaoncol.2018.7002 and PMC identifier 6459119.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study assesses the outcomes of single-patient use of the US Food and Drug Administration Expanded Access program.
Medical subject headings
- Antineoplastic Agents
- Compassionate Use Trials
- Drugs, Investigational
- Neoplasms